Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of human

BMC Genomics

Volumn 10, Issue SUPPL. 3, 2009, Pages

  Venkatachalam, Gireedhar ^a   Kumar, Alan P ^a   Yue, Loo S ^a   Pervaiz, Shazib ^b,c,d   Clement, Marie V ^a,b   Sakharkar, Meena K ^e,f  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d SINGAPORE MIT ALLIANCE   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^f NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SODIUM PROTON EXCHANGE PROTEIN 1; CATION TRANSPORT PROTEIN; SLC9A1 PROTEIN, HUMAN; SODIUM PROTON EXCHANGE PROTEIN; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA BINDING MOTIF; GENE CONTROL; IN VITRO STUDY; LIGAND BINDING; MATHEMATICAL ANALYSIS; MOUSE; NONHUMAN; PREDICTION; PROMOTER REGION; TRANSCRIPTION REGULATION; CHEMISTRY; COMPUTER SIMULATION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; TUMOR CELL LINE;

BINDING SITES; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; COMPUTER SIMULATION; HUMANS; MOLECULAR SEQUENCE DATA; PPAR GAMMA; PROMOTER REGIONS, GENETIC; SODIUM-HYDROGEN ANTIPORTER; SUPEROXIDE DISMUTASE;

ANTI-PROLIFERATIVE; BINDING MOTIF; COMPUTATIONAL IDENTIFICATION; EXPERIMENTAL VALIDATIONS; IN-VITRO; LIGAND BINDING; MALIGNANT CELLS; PROMOTER SEQUENCES; TRANSCRIPTION REGULATIONS;

GENES; LIGANDS; TRANSCRIPTION;

BIOINFORMATICS;

EID: 71549131007     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-10-S3-S5     Document Type: Article

References (32)

1. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006, 58(4):726-741. 10.1124/pr.58.4.5, 17132851.
2. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435. 10.1146/annurev.med.53.082901.104018, 11818483.
3. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999, 20(5):649-688. 10.1210/er.20.5.649, 10529898.
4. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45(2):120-159. 10.1016/j.plipres.2005.12.002, 16476485.
5. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347(6294):645-650. 10.1038/347645a0, 2129546.
6. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 1995, 92(17):7921-7925. 10.1073/pnas.92.17.7921, 41258, 7644514.
7. Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, Madden T, Andreeff M. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003, 63(18):5926-5939.
8. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391(6662):79-82. 10.1038/34178, 9422508.
9. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4(4):585-595. 10.1016/S1097-2765(00)80209-9, 10549290.
10. Noel J, Pouyssegur J. Hormonal regulation, pharmacology, and membrane sorting of vertebrate Na+/H+ exchanger isoforms. The American journal of physiology 1995, 268(2 Pt 1):C283-296.
11. Wakabayashi S, Shigekawa M, Pouyssegur J. Molecular physiology of vertebrate Na+/H+ exchangers. Physiol Rev 1997, 77(1):51-74.
12. Rotin D, Steele-Norwood D, Grinstein S, Tannock I. Requirement of the Na+/H+ exchanger for tumor growth. Cancer research 1989, 49(1):205-211.
13. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M, Alunni-Fabbroni M, Casavola V, Tommasino M. Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. Faseb J 2000, 14(14):2185-2197. 10.1096/fj.00-0029com, 11053239.
14. Pouyssegur J, Franchi A, Pages G. pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp 2001, 240:186-196. discussion 196-188., full_text, 11727929.
15. Bell SM, Schreiner CM, Schultheis PJ, Miller ML, Evans RL, Vorhees CV, Shull GE, Scott WJ. Targeted disruption of the murine Nhe1 locus induces ataxia, growth retardation, and seizures. The American journal of physiology 1999, 276(4 Pt 1):C788-795.
16. Akram S, Teong HF, Fliegel L, Pervaiz S, Clement MV. Reactive oxygen species-mediated regulation of the Na+-H+ exchanger 1 gene expression connects intracellular redox status with cells' sensitivity to death triggers. Cell death and differentiation 2006, 13(4):628-641. 10.1038/sj.cdd.4401775, 16179939.
17. Kumar AP, Chang MK, Fliegel L, Pervaiz S, Clement MV. Oxidative repression of NHE1 gene expression involves iron-mediated caspase activity. Cell death and differentiation 2007,
18. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004, 53(3):209-219. 10.1007/s00280-003-0726-5, 14610616.
19. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2000, 97(20):10990-10995. 10.1073/pnas.180329197, 27136, 10984506.
20. Oberley TD. Mitochondria, manganese superoxide dismutase, and cancer. Antioxid Redox Signal 2004, 6(3):483-487. 10.1089/152308604773934242, 15130275.
21. Jurka J, Milosavljevic A. Reconstruction and analysis of human Alu genes. Journal of molecular evolution 1991, 32(2):105-121. 10.1007/BF02515383, 1706781.
22. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. The Journal of biological chemistry 1996, 271(24):14412-14420. 10.1074/jbc.271.24.14412, 8662930.
23. Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(18):8229-8233. 10.1073/pnas.92.18.8229, 41130, 7667273.
24. Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. The Journal of biological chemistry 2004, 279(9):8300-8315. 10.1074/jbc.M311625200, 14668325.
25. Reynolds WF, Kumar AP, Piedrafita FJ. The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands. Biochemical and biophysical research communications 2006, 349(2):846-854. 10.1016/j.bbrc.2006.08.119, 1831877, 16956579.
26. Mukhopadhyay S, Das SK, Mukherjee S. Expression of Mn-Superoxide Dismutase Gene in Nontumorigenic and Tumorigenic Human Mammary Epithelial Cells. J Biomed Biotechnol 2004, 2004(4):195-202. 10.1155/S1110724304401016, 15467159, 555772.
27. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Possinger K, Koeffler HP. Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002, 74(2):155-165. 10.1023/A:1016114026769, 12186376.
28. St Clair D, Wan X, Kuroda M, Vichitbandha S, Tsuchida E, Urano M. Suppression of tumor metastasis by maganese superoxide dismutase is associated with reduced tumorigenicity and elevated fibronectin. Oncol Rep 1997, 4:753-757.
29. Ambrosone C. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000, 2:903-917. 10.1089/ars.2000.2.4-903, 11213491.
30. Kattan Z, Minig V, Leroy P, Dauca M, Becuwe P. Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res Treat 2008, 108(2):203-215. 10.1007/s10549-007-9597-5, 17473980.
31. Yeung BHY, Wong KY, Lin MC, Wong CKC, Mashima T, Tsuruo T, Wong AST. Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1//2. British journal of cancer 2008, 99(2):283-293. 10.1038/sj.bjc.6604477, 2480972, 18594523.
32. Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen YE, Schneider MD, Mangelsdorf DJ. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovascular research 2007, 76(2):269-279. 10.1016/j.cardiores.2007.06.027, 17678635.